Are there any emerging strategies to overcome these challenges?
To overcome resistance and improve efficacy, combination therapies are being explored. Combining CDK inhibitors with other targeted therapies, such as PI3K inhibitors or endocrine therapies, has shown promise in preclinical and clinical studies. Additionally, the development of next-generation CDK inhibitors with improved specificity and reduced side effects is an active area of research.
